Medical device company AirXpanders Inc (ASX:AXP) reported on Friday the receipt of marketing approval from the US Food and Drug Administration (FDA) 510(k) for the smooth shell version of the AeroForm Tissue Expander.
The company's AeroForm Tissue Expander System is used in patients undergoing two- stage breast reconstruction following mastectomy. AeroForm was granted US FDA de novo marketing authorization in 2016, subsequent US market clearance in 2017, first CE mark in Europe in 2012 and is currently licensed for sale in Australia.
Additionally, the company will evaluate the US launch plans and the timing for the AeroForm Smooth products.
In conjunction, the company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alternatives that could enhance stockholder value as well as to enable to continue serving patients and physicians.
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Oscotec receives ODD from FDA for Cevidoplenib
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
TELA Bio launches LIQUIFIX for US hernia surgery
BD boosts US syringe production amid healthcare demand
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT
Upgraded Syngene International biologics facility to start operation in 2024
BioXcel Therapeutics secures European patent for method to treat agitation in dementia